Cellectar stock climbs 8% on results for CNS malignancy therapy (NASDAQ:CLRB)

Cellectar Biosciences (NASDAQ:CLRB) stock jumped 8% in midday trading Monday after it reported positive results from a Phase 2b study of its phospholipid radiotherapeutic conjugate, iopofosine l 131, in the treatment of Waldenstrom’s macroglobulinemia, or WM.

The biotech company reported complete central nervous system, or CNS, clearance in a patient with WM with CNS involvement, also known as Bing-Neel Syndrome, who had previous BTKi exposure.

The company said the response further validates the potential of the product to treat CNS malignancies.